Whitby Jonathan, Nitchingham Anita, Caplan Gideon, Davis Daniel, Tsui Alex
MRC Unit for Lifelong Health and Ageing, University College London.
The Prince of Wales Clinical School, University of New South Wales.
Delirium (Bielef). 2022 Aug 9;1:36822. doi: 10.56392/001c.36822.
Delirium is associated with future dementia progression. Yet whether this occurs subclinically over months and years, or persistent delirium merges into worsened dementia is not understood. Our objective was to estimate the prevalence of persistent delirium and understand variation in its duration.
We adopted an identical search strategy to a previous systematic review, only including studies using a recognised diagnostic framework for ascertaining delirium at follow-up (persistent delirium). Studies included hospitalised older patients outside critical and palliative care settings. We searched MEDLINE, EMBASE, PsycINFO and the Cochrane Database of Systematic Reviews on 11th January 2022. We applied risk of bias assessments based on Standards of Reporting of Neurological Disorders criteria and assessed strength of recommendations using the grading of recommendation, assessment, development and evaluation (GRADE) approach. Estimates were pooled across studies using random-effects meta-analysis, and we estimated associations with follow-up duration using robust error meta-regression.
We identified 13 new cohorts, which we added to 10 from the previous systematic review (23 relevant studies, with 39 reports of persistent delirium at 7 time-points in 3186 individuals admitted to hospital care (mean age 82 years and 41% dementia prevalence). Studies were mainly at moderate risk of bias. Pooled delirium prevalence estimates at discharge were 36% (95% CI 22% to 51%, 13 studies). Robust error meta-regression did not show variation in prevalence of persistent delirium over time (-1.6% per month, 95% CI -4.8 to 1.6, p=0.08). Margins estimates for this model indicate a prevalence of persistent delirium of 16% (95% CI 6% to 25%) at 12 months.
This systematic review emphasises the importance of delirium as a persistent and extensive problem (GRADE certainty = moderate), raising questions on chronic delirium as a clinical entity and how it might evolve into dementia. Addressing persistent delirium will require a whole-system, integrated approach to detect, follow-up and implement opportunities for recovery across all healthcare settings.
谵妄与未来痴呆症的进展相关。然而,这是在数月和数年的亚临床阶段发生,还是持续性谵妄会演变为病情加重的痴呆症,目前尚不清楚。我们的目标是估计持续性谵妄的患病率,并了解其持续时间的差异。
我们采用了与之前的系统评价相同的检索策略,仅纳入那些在随访时使用公认的诊断框架来确定谵妄(持续性谵妄)的研究。研究对象包括在非重症和姑息治疗环境中住院的老年患者。我们于2022年1月11日检索了MEDLINE、EMBASE、PsycINFO和Cochrane系统评价数据库。我们根据《神经系统疾病报告标准》标准进行偏倚风险评估,并使用推荐分级、评估、制定和评价(GRADE)方法评估推荐强度。通过随机效应荟萃分析汇总各研究的估计值,并使用稳健误差元回归估计与随访持续时间的关联。
我们识别出13个新队列,并将其与之前系统评价中的10个队列合并(共23项相关研究,3186名住院患者在7个时间点有39份持续性谵妄报告,平均年龄82岁,痴呆症患病率为41%)。研究主要存在中度偏倚风险。出院时谵妄患病率的汇总估计值为36%(95%可信区间22%至51%,13项研究)。稳健误差元回归未显示持续性谵妄患病率随时间变化(每月-1.6%,95%可信区间-4.8至1.6,p=0.08)。该模型的边际估计值表明,12个月时持续性谵妄的患病率为16%(95%可信区间6%至25%)。
本系统评价强调了谵妄作为一个持续且广泛存在的问题的重要性(GRADE确定性=中等),引发了关于慢性谵妄作为一种临床实体以及它如何演变为痴呆症的问题。解决持续性谵妄需要一种全系统的综合方法,以在所有医疗环境中检测、随访并实施康复机会。